September 28, 2005 09:46 ET

Nymox Continues to Successfully Expand Extensive Patent Portfolio; Nymox's Product Development Pipeline Based on Several Hundred Patents and Applications Worldwide

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Sep 28, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company is continuing to successfully expand its broad worldwide patent portfolio in support of its proprietary product development programs. The Company pursues an aggressive patenting and patent licensing strategy to protect and expand upon its broad range of proprietary products and product development and drug discovery programs, according to the Company's General Counsel, Jack Gemmell. Currently Nymox and its subsidiaries have several hundred patents and patent applications in the U.S. and other countries around the world.

The Company's various drug candidates and targets are part of an extensive portfolio of patents and patent applications. Nymox has major proprietary drug development programs in Alzheimer's disease. One is aimed at spherons, tiny balls of dense protein found in the human brain and believed by Nymox scientists to be a major cause of senile plaques. Senile plaques are the pathological hallmark of Alzheimer's disease. Nymox has made a number of key discoveries about the link between spherons and Alzheimer's disease which have led to the development of spheron-based potential therapeutics for this fatal disease.

The Company also holds worldwide patent rights, including a U.S. patent, for the use of statin drugs for treating, preventing, and reducing the risk of the onset of Alzheimer's disease. Nymox holds important patent rights for its antibacterials in development, including potential treatments for E. coli O157 food contamination and infection.

Nymox markets three unique patent-protected products: AlzheimAlert™, a urine laboratory test which aids physicians in the diagnosis of Alzheimer's disease, and NicAlert™ and TobacAlert™, simple-to-use products which can be used on-site for the quick and accurate determination of tobacco use or exposure. NicAlert™ and TobacAlert™ employ patented technology which can reliably measure very small quantities of biochemical indicators in a variety of body fluids, including urine and saliva, using a convenient, easy-to-use strip test format. The Company is currently developing new diagnostic products based on this proprietary technology. The Company also has patented diagnostic markers and methods for osteoporosis and for the measurement of cholesterol levels using saliva samples.

AlzheimAlert™ measures the levels of a brain protein called neural thread protein or NTP which is known to be elevated in patients with Alzheimer's disease and which employs patented technology. The Company is also pursuing unique proprietary therapeutic agents that target the destructive effective of neural thread protein in the brains of Alzheimer's disease patients.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX